Partner With Us NRI

Procter & Gamble Health Ltd share Price

Company details

6M Return 28.10%
1Y Return 23.20%
Mkt Cap.(Cr) 8,639.78
Volume 5,774
Div Yield 1.01%
OI Chg %
Volume 5,774

Open Free Trading Account Online with ICICIDIRECT

Sustained efforts reflect in VMS traction…

About the stock

    Procter & Gamble Health is a leading pharma cum OTC company with key focus on vitamins, minerals, supplement (VMS) category.

    • It has legacy brands in the VMS category like Neurobion, Polybion, Evion (all vitamins), Livogen (iron supplement), Nasivion (nasal decongestant), Seven Seas (vitamin- substitute for malt based health drinks)
    • The company was earlier known as Merck Ltd and was part of Merck KGaA, Germany. In 2018 it (as a consumer health business) was acquired by P&G


    P&G Health's revenues grew on the back of 48%, 20% and 13% YoY growth in respiratory, gastro-intestinal and derma therapies, respectively, according to MAT March 2022, IQVIA. [note: It follows July-June fiscal year].

    • Sales were up 22% YoY to ₹ 267.8 crore
    • EBITDA was at ₹ 68.8 crore, up 123.8% YoY with margins at 25.7%

    Consequent PAT was at ₹ 51.2 crore (down 224.4% YoY)

Click here for full recommendation

Research view on more stocks

Procter & Gamble Health Ltd.

Q3FY23 Quarterly Result Announced for Procter & Gamble Health Ltd.

Pharmaceuticals firm Procter & Gamble Health announced Q3FY23 (quarter ending June) results:

  • Total sales of Rs 316.3 crore for the quarter ended March 31, 2023, vs Rs 262.2 crore, a year ago, up by 21%.
  • Profit After Tax (PAT) was Rs 59.2 crore, up by 16% vs a year ago.
  • Sales for the nine-month period ending March 31, 2023, was Rs 912.8 crore vs Rs 803.2 crore a year ago.
  • PAT for a nine-month period was Rs 199.7 crore vs Rs 151.4 crore a year ago, despite the high inflationary pressures

Mr. Milind Thatte, Managing Director, P&G Health India, said, “We continue to register a consistent growth in this quarter despite a challenging macro-economic environment. This has been made possible through our integrated growth strategies of expanded reach and improved productivity, while we continue to create awareness among our patients and consumers alike. The cornerstone of our approach continues to be our robust product line, which helps meet the rising demand for daily supplements, thereby helping us deliver the 6th consecutive quarter of strong growth. Our focus brands, Evion, Neurobion and Livogen continue to perform exceptionally well. The quarter also saw Neurobion regain its position as India’s No. 1 Nerve Care Brand, while Livogen’s exceptional performance continued behind the award winning campaign ‘Na Na Anemia’ with Diagnostic camps across the country. Under our flagship CSR Program, SEHAT, in partnership with Tata Trust’s ‘Yes! To Poshan’Program, we continued to showcase our commitment towards the cause of maternal & child health.”.

“The quarter also saw us receive various prestigious recognitions. We are thankful to the CSR Summit and Awards 2023, CII, Exchange4media and Obesity International for recognizing our Corporate Social Responsibility and Consumer Awareness efforts. These recognitions have further fueled our passion and commitment to serve Indian consumers and help them live healthier lives,” he concluded.




Result PDF

View Other Company Results


Investment recommendation

Sustained efforts reflect in VMS traction…
Call Date
06 Feb 2023
Entry Price 4,580.00
Target Price 5,315.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Procter & Gamble Health Ltd Stocks COMPARISION


Equity Capital: 616.49 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 943.10 32,637.51
LAST 3M 17,174.81 50,737.17
LAST 6M 66,045.02 26,732.81
LAST 12M 121,409.17 72,523.78

Procter & Gamble Health Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Proctor & Gamble Health Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 8,936.24 crores, it was incorporated in the year 1967. It has reported consolidated sales of Rs. 22,239.0 crores in March’2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 500126 and is listed on the National Stock Exchange (NSE) with the code PGHL.

    Proctor & Gamble Health Ltd, originally incorporated under the name Merck Ltd, is involved in manufacturing and supplying pharmaceuticals and chemicals. The company's pharmaceuticals division is involved in producing prescription drugs, biotechnology products, and consumer health products. At the same time, the chemicals division is involved in supplying pharmaceutical chemicals, formulated chemical products, industrial chemicals, and other chemical products. Proctor & Gamble completed the acquisition of Merck Ltd in December’2018. Its manufacturing facility is established in Goa. Proctor & Gamble Health Ltd, in pursuing the Corporate Social Responsibility requirements, have introduced various health and education schemes aimed at underprivileged children and women of the country. The promoters of the company own 51.82% of the stake in the company, Foreign Institutional Investors (FII) own 6.45%, Domestic Institutional Investors (DII) own 11.81% stake in the company, and others (such as public & retail investors) hold the balance of 29.92%.

    In March 2021, quarterly net revenue was Rs. 219.15 crores, which has decreased marginally by approximately 3.93 % from Rs. 228.11 crores for the January-March 2020 quarter. The quarterly net profit in March 2021 was Rs. 15.17 crores, which has reduced and decreased by nearly 67.35% from a net profit of Rs. 46.46 crores in March 2020. In March 2021, the reported operating profit was at Rs. 138.29 crores, which is also decreased by 19.76% as compared to an operating profit of Rs. 172.34 crores for the quarter ending in March 2020. From an EPS of Rs. 28 in March 2020, the EPS of Proctor & Gamble Health Ltd has reduced and reached Rs. 9.5 per share in March 2021. PGHL's stock closed at Rs. 5,383.60 on 20th August’2021 (NSE) and has given a negative return of 23.78% in the last six months and an annual return of 14.67% in the previous year.

Registered Address

Godrej One 8th Floor, Projshanagar Vikhroli (East), Mumbai, Maharashtra, 400079

Tel : 91-22-62109000
Email : investorgrievance.im:pg.com
Website : http://www.pghealthindia.com

Sharepro Services India P Ltd

AGM Date (Month) : Nov
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 500126
Book Closure Date (Month) :
BSE Group : A
ISIN : INE199A01012

FAQ’s on Procter & Gamble Health Ltd Shares

You can buy Procter & Gamble Health Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Procter & Gamble Health Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 30, 2023 01:29 PM the closing price of Procter & Gamble Health Ltd was ₹ 5,205.00.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 30, 2023 01:29 PM, the market cap of Procter & Gamble Health Ltd stood at ₹ 8,639.78.

The latest PE ratio of Procter & Gamble Health Ltd as of May 30, 2023 01:29 PM is 35.75

The latest PB ratio of Procter & Gamble Health Ltd as of May 30, 2023 01:29 PM is 0.09

The 52-week high of Procter & Gamble Health Ltd is ₹ 5,249.00 while the 52-week low is ₹ 3,870.10

According to analyst recommendations, Procter & Gamble Health Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app